Hyperinsulinism
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Hyperinsulinism Classification and external resources | |
| ICD-10 | E15., E16.1 |
|---|---|
| ICD-9 | 251.1 |
| DiseasesDB | 20590 |
| eMedicine | ped/1075 |
| MeSH | D006946 |
|
WikiDoc Resources for Hyperinsulinism | |
|
Articles | |
|---|---|
|
Most recent articles on Hyperinsulinism Most cited articles on Hyperinsulinism | |
|
Media | |
|
Powerpoint slides on Hyperinsulinism | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Hyperinsulinism at Clinical Trials.gov Trial results on Hyperinsulinism Clinical Trials on Hyperinsulinism at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Hyperinsulinism NICE Guidance on Hyperinsulinism
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Hyperinsulinism Discussion groups on Hyperinsulinism Patient Handouts on Hyperinsulinism Directions to Hospitals Treating Hyperinsulinism Risk calculators and risk factors for Hyperinsulinism
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Hyperinsulinism | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Hyperinsulinism or hyperinsulinemia refers to an above normal level of insulin in the blood of a person or animal. Normal insulin secretion and blood levels are closely related to the level of glucose in the blood, so that a given level of insulin can be normal for one blood glucose level but low or high for another. Hyperinsulinism can be associated with several types of medical problems, which can be roughly divided into two broad categories: those tending toward reduced sensitivity to insulin and high blood glucose levels (hyperglycemia), and those tending toward excessive insulin secretion and low glucose levels (hypoglycemia).
Hyperinsulinism due to diminished sensitivity, associated with diabetes risk
Although many factors influence insulin secretion, the most important control is the amount of glucose moving from the blood into the beta cells of the pancreas. In healthy people, even small rises in blood glucose result in increased insulin secretion. As long as the pancreatic beta cells are able to sense the glucose level and produce insulin, the amount of insulin secreted is usually the amount required to maintain a fasting blood glucose between 70 and 100 mg/dL (3.9-5.6 mmol/L) and a non-fasting glucose level below 140 mg/dL (<7.8 mmol/L).
When liver cells and others that remove glucose from the blood become less sensitive and more resistant to the insulin, the pancreas increases secretion and the level of insulin in the blood rises. This increased secretion can compensate for reduced sensitivity for many years, with maintenance of normal glucose levels. However, if insulin resistance worsens or insulin secretion ability declines, the glucose levels will begin to rise. Persistent elevation of glucose levels is termed diabetes mellitus.
Typical fasting insulin levels found in this type of hyperinsulinism are above 20 μU/mL. When resistance is severe, levels can exceed 100 μU/mL.
In addition to being a risk factor for type 2 diabetes, hyperinsulinism due to insulin resistance may increase blood pressure and contribute to hypertension by direct action on vascular endothelial cells (the cells lining blood vessels). Hyperinsulinism has also been implicated as a contributing factor in the excessive production of androgens in polycystic ovary syndrome.
The principal treatments of hyperinsulinism due to insulin resistance are measures that improve insulin sensitivity, such as weight loss, physical exercise, and drugs such as thiazolidinediones or metformin.
Hyperinsulinism due to inappropriate secretion, associated with hypoglycemia
Hyperinsulinism is also used in medical contexts to refer to forms of hypoglycemia caused by excessive insulin secretion. In normal children and adults, insulin secretion should be minimal when blood glucose levels fall below 70 mg/dL (3.9 mM). There are many forms of hyperinsulinemic hypoglycemia caused by various types of insulin excess. Some of those that occur in infants and young children are termed congenital hyperinsulinism. In adults, severe hyperinsulinemic hypoglycemia is often due to an insulinoma, an insulin-secreting tumor of the pancreas.
Insulin levels above 3 μU/mL are inappropriate when the glucose level is below 50 mg/dL (2.8 mM), and may indicate hyperinsulinism as the cause of the hypoglycemia. The treatment of this form of hyperinsulinism depends on the cause and the severity of the hyperinsulinism, and may include surgical removal of the source of insulin, or a drug such as diazoxide or octreotide that reduces insulin secretion.
Dr. Seale Harris first diagnosed hyperinsulinism in 1924 [1] and also is credited with the recognition of spontaneous hypoglycemia.[2]
Hyperinsulinism due to insulin injection
The treatment of diabetes mellitus with insulin replacement therapy can easily result in diabetic hypoglycemia due to the difficulty of balancing insulin delivery.
Transient hyperinsulinism can also occur when insulin is injected by non-diabetic athletes attempting to enhance their anaerobic performance.
References
- ↑ Restore Your Health Safely and Sensibly. Liteforlife.com. Retrieved on 2007-02-24.
- ↑ Seale Harris. Alabama State Archives. Retrieved on 2007-02-24.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
